AVITA Medical (RCEL) Common Equity (2018 - 2025)

AVITA Medical's Common Equity history runs 8 years deep, the most recent figure standing at -$16.6 million for Q4 2025.

• Quarterly Common Equity fell 470.08% year-over-year to -$16.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.6 million (down 470.08% YoY) and the FY2025 annual result came in at -$16.6 million, down 470.08% from the prior year.
• Common Equity was -$16.6 million for Q4 2025 at AVITA Medical, down from -$6.7 million in the prior quarter.
• Across five years, Common Equity topped out at $118.9 million in Q1 2021 and bottomed at -$16.6 million in Q4 2025.
• A 5-year average of $55.2 million and a median of $65.8 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 75.55% — and 2025, when it plunged 470.08%.
• AVITA Medical's Common Equity stood at $104.6 million in 2021, then declined by 19.01% to $84.7 million in 2022, then sank by 42.11% to $49.1 million in 2023, then plunged by 90.83% to $4.5 million in 2024, then plunged by 470.08% to -$16.6 million in 2025.
• Business Quant data shows RCEL's Common Equity at -$16.6 million in Q4 2025, -$6.7 million in Q3 2025, and -$12.9 million in Q2 2025.